Clinical characteristics and methods of treatment of patients with stable coronary heart disease in the primary care setting - The results of the Polish, multicentre Angina Treatment Pattern (ATP) study

International Journal of Clinical Practice

Volumn 58, Issue 12, 2004, Pages 1127-1133

  Ruzyllo, Witold ^a   Ponikowski, P ^b   Wilkins, A ^c  

^a INSTITUTE OF CARDIOLOGY   (Poland)

^b MILITARY HOSPITAL   (Poland)

^c Medical Information Department   (Poland)

Author keywords

Anginal symptoms; Anti anginal therapy; ATP survey; Stable coronary heart disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LONG ACTING DRUG; NITRIC ACID DERIVATIVE; TRIMETAZIDINE;

ADULT; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CIGARETTE SMOKING; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; DISEASE DURATION; DYSLIPIDEMIA; ECG ABNORMALITY; EPIDEMIOLOGICAL DATA; EXERCISE TEST; FAMILY HISTORY; FEMALE; HEALTH SURVEY; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; MONOTHERAPY; OBESITY; PHYSICIAN; POLAND; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGINA PECTORIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NITROGLYCERIN; PHYSICIAN'S PRACTICE PATTERNS; POLAND; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; VASODILATOR AGENTS;

EID: 12344266076     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2004.00234.x     Document Type: Article

References (30)

1. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouuyel P, for the WHO MONICA Project. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet 1999; 353: 1547-57.
2. Zatonski WA, McMichael AJ, Powles JW. Ecological study of reasons for sharp decline in mortality from ischaemic heart disease in Poland since 1991. BMJ 1998; 316: 1047-51.
3. Vartiainen E, Puska P, Pekkanen J, Tuomilehto J, Jousilahti P. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. BMJ 1994; 309: 23-7.
4. Wilhelmsen L, Johansson S, Ulvenstam G et al. CHD in Sweden: mortality, incidence and risk factors over 20 years in Gothenburg. Int J Epidemiol 1989; 18 (Suppl. 1): S101-8.
5. Task Force of the European Society of Cardiology. Management of stable angina pectoris. Eur Heart J 1997; 18: 394-413.
6. ACC/AHA/ACP-ASIM. Guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on management of patients with chronic stable angina). Circulation 1999; 99: 2829-48.
7. Guidelines of the Prevention Committee of the Polish Cardiac Society. Prevention of coronary heart disease. Kardiol Pol 2000; 53 (Suppl. I): I-1-I-48.
8. Shepherd J. From best evidence to best practice - what are the obstacles? Atherosclerosis 1999; 147 (Suppl. I): S45-S51.
9. Pearson TA, Peters TD. The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient. Am J Cardiol 1997; 80: 45H-52H.
10. Standards for management of cardiovascular diseases of the Polish Cardiac Society (coronary heart disease). Kardiol Pol 1997; 46 (Suppl. 1): 1-7.
11. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
12. HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
13. Ferrari R. Effect of ACE inhibition on myocardial ischaemia. Eur Heart J 1998; 19 (Suppl. G): G41-7.
14. Pepine CJ, Abrams J, Marks RG et al. Characteristics of a contemporary population with angina pectoris. Am J Cardiol 1994; 74: 226-31.
15. EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease. Principal results. Eur Heart J 1997; 18: 1569-82.
16. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22 554-72.
17. Campbell NC, Thain J, Deans HG, Ritchie LD, Rawles JM. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ 1998; 316: 1430-4.
18. Kannel WB. Coronary heart disease risk factors in the elderly. Am J Geriatr Cardiol 2002; 11: 101-7.
19. Hippisley-Cox J, Pringle M, Crown N, Meal A, Wynn A. Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. BMJ 2001; 322: 832.
20. Petrie MC, Dawson NF, Murdoch DR, Davie AP, McMurray JJV. Failure of women's heart. Circulation 1999; 99: 2334-41.
21. ASPIRE Steering Group. A British cardiac society survey of the potential for the secondary prevention of coronary artery disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996; 75: 334-42.
22. Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2001; 161: 1621-8.
23. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. European Action on Secondary Prevention to Reduce Events. Lancet 2001; 357: 995-1001.
24. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
25. Akhras F, Jackson G. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet 1991; 338: 1036-9.
26. Savonito S, Ardissino D, Egstrup K et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol 1996; 27: 3116.
27. Fox KM, Mulcahy D, Findlay I et al. The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. Eur Heart J 1996; 17: 96-103.
28. Jackson G. Combination therapy in angina: a review of combined haemodynamic treatment and the role for combined haemodynamic and cardiac metabolic agents. Int J Clin Pract 2001; 55: 256-61.
29. Cannon PJ, Connell PA, Stockley IH et al. Prevalence of angina as assessed by a survey of prescription of nitrates. Lancet 1988; i: 979-81.
30. LaCroix AZ, Guralnik JM, Curb JD et al. Chest pain and coronary heart disease mortality among older men and women in three communities. Circulation 1990; 81: 437-46.